gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 27 Aug 2015.

Apolipoprotein A-Ia

apolipoprotein A-I, apoA-I
Top mentioned proteins: HDL, Apo, CAN, HAD, fibrillin-1
Papers on apolipoprotein A-I
Cellular Interaction and Cytotoxicity of the Iowa Mutation of Apolipoprotein A-I (ApoA-IIowa) Amyloid Mediated by Sulfate Moieties of Heparan Sulfate.
Sakashita et al., Tokushima, Japan. In J Biol Chem, 19 Sep 2015
UNASSIGNED: The single amino acid mutation G26R in human apolipoprotein A-I (apoA-I) is associated with familial amyloid polyneuropathy (FAP) III.
Apolipoprotein A-I inhibits experimental colitis and colitis-propelled carcinogenesis.
Eliopoulos et al., Irákleion, Greece. In Oncogene, 17 Sep 2015
Guided by this finding, we have further interrogated the expression and function of one of these genes, apolipoprotein A-I (ApoA-I), a major component of high-density lipoprotein.
Lipid-free Apolipoprotein A-I Structure: Insights into HDL Formation and Atherosclerosis Development.
Atkinson et al., Boston, United States. In Arch Med Res, 31 Jul 2015
Knowledge of the high-resolution structure of full-length apoA-I is vital for a molecular understanding of the function of HDL at the various steps of the RCT pathway.
Innovative pharmaceutical interventions in cardiovascular disease: focusing on the contribution of non-HDL-C/ LDL-C-lowering versus HDL-C-raising A systematic review and meta-analysis of relevant preclinical studies and clinical trials.
Wouter Jukema et al., Leiden, Netherlands. In Eur J Pharmacol, Jun 2015
Nonetheless, treatment strategies aimed at improving HDL function and raising apolipoprotein A-I may be worth exploring.
Structural stability and functional remodeling of high-density lipoproteins.
Gursky, Boston, United States. In Febs Lett, Apr 2015
A mechanism for the conformational adaptation of the major HDL proteins, apoA-I and apoA-II, to the increasing lipid load is proposed.
Cell-free expression of functional receptor tyrosine kinases.
Coleman et al., Sacramento, United States. In Sci Rep, Dec 2014
Here we describe a rapid cell-free and detergent-free co-translation method for producing full-length and functional ERBB2 and EGFR receptor tyrosine kinases supported by water-soluble apolipoprotein A-I based nanolipoprotein particles.
ApoA-I mimetics.
Hovingh et al., Amsterdam, Netherlands. In Handb Exp Pharmacol, Dec 2014
ApoA-I, the major protein component of HDL, is considered to play an important role in many of the antiatherogenic functions of HDL, most notably reverse cholesterol transport (RCT), and several therapies have been developed to mimic apoA-I function, including administration of apoA-I, mutated variants of apoA-I, and apoA-I mimetic peptides.
HDL in infectious diseases and sepsis.
Norata et al., Cinisello Balsamo, Italy. In Handb Exp Pharmacol, Dec 2014
Pharmacological studies support the benefit of recombinant HDL or apoA-I mimetics during bacterial infection, while apoL-1-nanobody complexes were tested for trypanosome infection.
Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial.
Alexander et al., Lexington, United States. In J Am Heart Assoc, Dec 2014
BACKGROUND: CSL112 is a new formulation of human apolipoprotein A-I (apoA-I) being developed to reduce cardiovascular events following acute coronary syndrome.
Self-efficacy regarding physical activity is superior to self-assessed activity level, in long-term prediction of cardiovascular events in middle-aged men.
Schmidt et al., Göteborg, Sweden. In Bmc Public Health, Dec 2014
Multivariate analyses showed that poor physical self-efficacy was associated with an increased relative risk of 2.0 (95 % CI 1.2 to 3.0), of having a cardiovascular event during follow-up also after adjustments for co-variates such as waist to hip ratio, heart rate, fasting plasma glucose, serum triglycerides, systolic blood pressure, apoB/apoA-I ratio and leisure-time physical activity.
Plasma lipids, genetic variants near APOA1, and the risk of infantile hypertrophic pyloric stenosis.
Melbye et al., Copenhagen, Denmark. In Jama, 2013
P = 1.9 × 10(-10)), is located 301 bases downstream of the apolipoprotein A-I (APOA1) gene and is correlated (r2 between 0.46 and 0.80) with SNPs previously found to be associated with levels of circulating cholesterol.
Control of angiogenesis by AIBP-mediated cholesterol efflux.
Miller et al., San Diego, United States. In Nature, 2013
To prevent cholesterol overload, ATP-binding cassette (ABC) transporters mediate cholesterol efflux from the cells to apolipoprotein A-I (apoA-I) and the apoA-I-containing high-density lipoprotein (HDL).
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.
Singh-Jasuja et al., Tübingen, Germany. In Nat Med, 2012
Furthermore, among six predefined populations of myeloid-derived suppressor cells, two were prognostic for overall survival, and among over 300 serum biomarkers, we identified apolipoprotein A-I (APOA1) and chemokine (C-C motif) ligand 17 (CCL17) as being predictive for both immune response to IMA901 and overall survival.
Lipid-related markers and cardiovascular disease prediction.
Danesh et al., In Jama, 2012
OBJECTIVE: To determine whether adding information on apolipoprotein B and apolipoprotein A-I, lipoprotein(a), or lipoprotein-associated phospholipase A2 to total cholesterol and high-density lipoprotein cholesterol (HDL-C) improves cardiovascular disease (CVD) risk prediction.
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.
Rader et al., Philadelphia, United States. In N Engl J Med, 2011
RESULTS: The levels of HDL cholesterol and apolipoprotein A-I were significant determinants of cholesterol efflux capacity but accounted for less than 40% of the observed variation.
Rapid incorporation of functional rhodopsin into nanoscale apolipoprotein bound bilayer (NABB) particles.
Sakmar et al., New York City, United States. In J Mol Biol, 2008
The NABB system using engineered zebrafish apo A-I is a native-like membrane mimetic system for G-protein-coupled receptors.
share on facebooktweetadd +1mail to friends